COLUMBUS, Ohio – Dr. John Byrd, a nationally renowned leukemia specialist and researcher at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, received the Emil J Freireich Award for clinical cancer research earlier this month.
This award is given to candidates 55 and younger who have made outstanding contributions to clinical research. Byrd, who is director of the hematologic malignancy program and member of the experimental therapeutics program, was selected from a broad range of candidates within the areas of clinical research in hematology and solid tumors. The award is presented annually during the MD Anderson-sponsored Foundations of Clinical Cancer Research event each March.
The first Freireich Award was made possible by former fellows and colleagues who wanted to commemorate Freireich’s contributions to clinical cancer research by honoring a young, clinical scientist whose work carries on his tradition.
The award recognized Byrd for his research accomplishments with several therapeutic agents active in chronic lymphocytic leukemia (CLL) and related leukemia and lymphoma. He is also a leader in laboratory and clinical investigation of immune-based therapies for the treatment of CLL and lymphoma.
For the second time since the award was established in 1997, an Ohio State cancer researcher received the award. In 1998, Dr. Michael A. Caligiuri, director of the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, received the Freireich award.
In 2001, Byrd was recruited to Ohio State where he was appointed the director of hematologic malignancies. He also holds the D. Warren Brown chair in leukemia research and is a professor of medicine and medicinal chemistry.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (cancer.osu.edu) strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report.
Contact: Alexis Shaw, Medical Center Public Affairs and Media Relations,614-293-3737 or Alexis.Shaw2@osumc.edu